

03-20-2002

2/5




Form PTO-1595 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) Tab settings

U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

102024061

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.



1. Name of conveying party(ies): Dendreon Corporation 3005 First Avenue Seattle, WA 98121

2. Name and address of receiving party(ies) Name: Transamerica Technology Finance Corporation Internal Address:

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment Merger Security Agreement Change of Name Other

Street Address: 76 Batterson Park Rd.

City Farmington State: CT Zip: 06032

Execution Date: March 8, 2002

Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 09/344,195

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name:

Internal Address:

Street Address:

City: State: Zip:

6. Total number of applications and patents involved: 5

7. Total fee (37 CFR 3.41).....\$

- Enclosed Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Allen Sailer

Name of Person Signing

Allen M. Sailer 3/8/02

Signature

Date

03/19/2002 00000145 09344195 Total number of pages including cover sheet, attachments, and documents: 6

01 FC:581

240.00 OP

Mail documents to be recorded with required cover sheet information to: Commissioner of Patents & Trademarks, Box Assignments Washington, D.C. 20231

PATENT REEL: 012676 FRAME: 0668

Additional Dendreon Patent Information  
June, 2001 to January, 2002

- 1. Immunostimulatory Composition and Method  
Application Number 09/344,195, United States  
Issued April 30, 2001
- 2. Cell Washing Device and Method  
Application Number 09/118,326, United States  
Issued March 6, 2001
- 3. Cell Washing Device and Method  
Application Number 337472, New Zealand  
Issued August 9, 2001
- 4. Prostate Tumor Polynucleotide and Antigen Compositions  
Application Number 09/112,096  
Issued February 7, 2001
- 5. Compositions and Methods for Enhancement of Major Histocompatibility  
Complex Class I Restricted Antigen Presentation  
Application Number 999642598  
Publication Number 1141007  
Issued October 10, 2001
- 6. Selective Apoptosis of Neoplastic Cells by an HLA-DR Specific  
Monoclonal Antibody  
Application Number 09/929,209  
Issued December 12, 2001

**SUPPLEMENT TWO  
TO  
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This SUPPLEMENT TWO TO INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement"), dated as of March 8, 2002, is entered into between **DENDREON CORPORATION**, a Delaware corporation ("Grantor"), which has a mailing address at 3005 First Avenue, Seattle, Washington 98121 and **TRANSAMERICA TECHNOLOGY FINANCE CORPORATION**, successor in interest to Transamerica Business Credit Corporation, a Delaware corporation ("TTFC"), having its principal office at 9399 West Higgins Road, Suite 600, Rosemont, Illinois 60018, and having an office at 76 Batterson Park Road, Farmington, Connecticut 06032.

**RECITALS**

A. Grantor and TTFC previously entered into an Intellectual Property Security Agreement dated as of August 3, 1999 and a Supplement One to Intellectual Property Security Agreement dated June 6, 2001 (collectively, the "Original Agreement"), which was recorded in the U.S. Patent and Trademark Office with respect to the trademarks and patents identified therein;

B. Grantor and TTFC also previously entered into a Loan and Security Agreement dated July 30, 1999, Security Agreement dated June 6, 2001, and Master Lease Agreements dated December 11, 1997, as amended May 28, 1999, and June 6, 2001, and other instruments, documents and agreements contemplated thereby or related thereto (collectively, together with the Original Agreement, the "Loan and Lease Documents"). Pursuant to the Loan and Lease Documents, Grantor has granted to TTFC a security interest in, among other things, all of Grantor's present and future general intangibles, including, without limitation, trademarks, patents and other "Intellectual Property Collateral" (as defined in the Original Agreement);

C. Grantor and TTFC desire to supplement the Original Agreement to make specific reference to the trademarks, patents and other intellectual property set forth below. The Original Agreement shall continue in full force and effect with respect to the Intellectual Property Collateral described therein. By entering into this Supplement, the parties do not intend to imply that the trademarks, patents and other intellectual property set forth below are not covered and perfected by the existing Loan and Lease Documents, including, without limitation, the Original Agreement.

NOW THEREFORE, for valuable consideration, the parties hereto mutually agree as follows:

1. Exhibit A and Exhibit B of the Original Agreement are hereby supplemented by the addition of the intellectual property set forth on Exhibit A attached hereto, so that the "Intellectual Property Collateral" (as defined in the Original Agreement) includes, without limitation, all of the intellectual property set forth in Exhibit A and Exhibit B to the Original Agreement and all of the intellectual property set forth in Exhibit A hereto.

2. Grantor confirms its grant to TTFC of a security interest in all of Grantor's right, title and interest in the Intellectual Property Collateral, including, without limitation, all of the intellectual property set forth in Exhibit A and Exhibit B to the Original Agreement and all of the intellectual property set forth in Exhibit A hereto, to secure the payment and performance of all "Obligations" (as defined in the Loan and Lease Documents).

3. The Grantor represents and warrants that Exhibit A and Exhibit B to the Original Agreement, together with Exhibit A hereto, constitute a true and complete schedule of all federal and state trademark and patent registrations, and pending registrations and applications, owned or controlled by Grantor or licensed to Grantor.

4. Except as modified herein, all terms and conditions of the Original Agreement shall continue in full force and effect, and Grantor represents and warrants to TTFC that all representations and warranties set forth in the Original Agreement, as supplemented hereby, are true and correct. This Supplement is an integral part of the Original Agreement.

IN WITNESS WHEREOF, this Supplement has been executed as of the date first written above.

Grantor:

Accepted:

**DENDREON CORPORATION**

By *Maureen A. Minoretto*  
Title CEO

**TRANSAMERICA TECHNOLOGY  
FINANCE CORPORATION, successor  
in interest to Transamerica Business  
Credit Corporation**

By *Allen M. Sailer*  
Title Allen M. Sailer  
Sr. Vice President

SUPPLEMENTAL LIST OF REGISTERED  
AND PENDING TRADEMARKS

NO SUPPLEMENTAL TRADEMARK INFORMATION

SUPPLEMENTAL LIST OF PATENTS  
AND PATENT APPLICATIONS

See attached.

Additional Dendreon Patent Information  
June, 2001 to January, 2002

1. Immunostimulatory Composition and Method  
Application Number 09/344,195, United States  
Issued April 30, 2001
2. Cell Washing Device and Method  
Application Number 09/118,326, United States  
Issued March 6, 2001
3. Cell Washing Device and Method  
Application Number 337472, New Zealand  
Issued August 9, 2001
4. Prostate Tumor Polynucleotide and Antigen Compositions  
Application Number 09/112,096  
Issued February 7, 2001
5. Compositions and Methods for Enhancement of Major Histocompatibility  
Complex Class I Restricted Antigen Presentation  
Application Number 999642598  
Publication Number 1141007  
Issued October 10, 2001
6. Selective Apoptosis of Neoplastic Cells by an HLA-DR Specific  
Monoclonal Antibody  
Application Number 09/929,209  
Issued December 12, 2001